spacer
home > ebr > summer 2018 > gene therapy
PUBLICATIONS
European Biopharmaceutical Review

Gene Therapy

In 2014, following a quarter of a century roller coaster trajectory, Ledley et al published very optimistic conclusions after their examination of life cycles of gene therapy, stating “Gene therapy technologies are now achieving the level of maturity that innovation research and biotechnology experience suggest may be requisite for efficient product development” (1). Looking at the following, it seems that reality meets those odds:

• The first marketing authorisations granted in the Western countries (Strimvelis® for the rare immunodeficiency syndrome adenosine-deaminase-severe combined immunodeficiency (ADA-SCID), Imlygic® [HSV1-GMCSF] for melanoma, Kymriah® for acute leukocytic leukemia, Yescarta® for non-Hodgkin lymphoma, Luxturna® for Leber congenital amaurosis)
• The steady maturation of the field since the 1980s (>40,000 papers, nearly 20,000 patents, >2,500 clinical trials including >100 late stage Phase 2/3 or Phase 3 trials)
• Billions in capital investments and initial public offerings (IPOs) in gene therapy companies, the activity being now driven by large pharmaceutical companies (with a peak reached recently with the $8.7 billion acquisition of Avexis by Novartis)

Gene therapy is defined as the introduction of genetic material into patients with an intended curative, life-extending, or life-enhancing therapeutic benefit. The applications rely on a myriad of possibilities, including the transient or permanent genetic modification of the administered product or ex vivo-engineered tissue to produce proteins for internal, local, or systemic use, helping to replace or correct faulty genes (in the case of rare diseases), providing stimuli to regenerate tissues (in the case of brain or cardiac disorders), killing tissues, or enhancing defence mechanisms (in the case of cancer or infectious diseases).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Serge Braun PharmD, PhD, is Scientific Director of AFM-Téléthon, President of Genosafe (a CRO company dedicated to quality control of biotherapeutic products) and Director Neuromuscular diseases at Généthon. He has 10 years of experience in the neuromuscular diseases field in the academic sector and 10 years in the biotech sector as Vice President of Research of Transgene SA. Serge was also co-founder of Neurofit, a CRO specialised in preclinical testings, and Vice President of Alsace BioValley, the non-profit making organisation for the development of a major biotech cluster in Europe. He also serves as advisor for Venture Capital companies and bioclusters.
spacer
Dr Serge Braun
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

TrialScope Announces Partnership with Greater Gift

JERSEY CITY, NJ – May 14, 2019 – TrialScope, the global leader in clinical trial transparency, disclosure compliance and patient engagement solutions, has partnered with Greater Gift to donate vaccines to children in need.
More info >>

White Papers

Shipping with Active Packaging Containers: Three Pre-flight Decisions that Impact the Success of High-value Global Shipments

World Courier

It is the dead of winter in the northern hemisphere and the height of summer in the southern, with external temperature fluctuations exceeding 50 degrees. Flight delays have added precious days to the transport of your multi-million dollar shipment of blockbuster drug from South East Asia destined for Russia. In France, the roads are closed for days due to a monster snowstorm, with your irreplaceable shipment of investigational drugs stopped somewhere en route between Paris and the clinical trial site. Will all be lost, or can informed choices made before the shipment departs ensure product safety despite unforeseen circumstances?
More info >>

 
Industry Events

World Vaccine Congress Europe

28-31 October 2019, Barcelona, Spain

The 20th annual World Vaccine Congress Europe is taking place 28-31 Oct in Barcelona. It’s the biggest and most established European vaccine event with over 250 speakers, 700+ senior vaccine attendees, hundreds of networking hours. It cover key topics across the complete vaccine value chain bringing together: • Government • big pharma • big biotech • SME Biotech • academia and the wider service provider community and their partners to discuss scientific, clinical and strategic advances and opportunities. The event has already confirmed over 200 speakers from Human Vaccine Project, OECD, CEPI, European Commission, FDA, WHO, OECD, NIH, GSK and many more… There is a Super Early Bird offer available – Find Out More www.terrapinn.com/WVCEU/EBR
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement